Mielóma multiplex: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• BCMA 134
• CD38 22
• GPRC5D 36
• CD19 31
• TP53 0
• STAT3 0
• CXCR4 4
• MYC 0
• BCL-2 2
• PI3K 1
• mTOR 0
• IL-6 0
• STING 0
• BRAF 2
• CD47 1
• HDAC 0
• AKT 0
• PD-1 1
• PD-L1 1
• CD20 3
• GLP-1 0
• JAK 0
• PTEN 0
• SGLT2 0
• TIGIT 0
• AMPK 0
• B7-H3 0
• NRAS 1
• CTLA-4 1
• ERK 0
• EZH2 0
• FTO 0
• IL-15 3
• JNK 0
• KRAS 1
• MAPK 0
• RAS 0
• CD22 2
• CD33 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• LAG-3 0
• MDM2 0
• METTL3 0
• NRF2 0
• BRCA1 0
• BRD4 0
• BTK 1
• CD123 1
• CD30 0
• CDK4/6 0
• GPX4 0
• HER2 0
• HIF-1 0
• HSP90 0
• MEK 0
• MET 0
• MUC1 0
• NTRK 0

58+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)

  Universita Degli Studi di Parma· Parma, Olaszország· EU contribution 193 643 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the immuno-regulatory functions of the human bone marrow niche upon cancer cellular therapy (ImmunhOss)

  Lunds Universitet· Lund, Svédország· EU contribution 2 000 000 EUR· until 2032. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Microbiome-Driven Modulation of Immune Reconstitution and Vaccine Responsiveness in Multiple Myeloma Patients following Stem Cell Transplantation (MicroMM)

  Technische Universitaet Muenchen· Muenchen, Németország· EU contribution 1 466 571 EUR· until 2031. okt.

• European Commission (Horizon Europe) · HORIZON-RIA

  iNK Cell–Driven Strategies for Enhanced Multiple Myeloma ImmunotherapY (iN-KEY)

  Banc de Sang I Teixits· Barcelona, Spanyolország· EU contribution 9 998 178 EUR· until 2031. szept.· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A CEllulaR immunoTherapy virtuAl twin for personalIsed cancer treatmeNT (CERTAINTY)

  Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev· Munchen, Németország· EU contribution 9 999 253 EUR· until 2028. máj.· 8 countries

5 of 7 running projects, newest first. Listed amounts together: 35,6 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment

  NCT07195617· Guangzhou Bio-gene Technology Co., Ltd· Frissítve: 2026. máj. 28.

  “Due to corporate strategic adjustment.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma

  NCT07196124· Guangzhou Bio-gene Technology Co., Ltd· Frissítve: 2026. máj. 28.

  “Due to corporate strategic adjustment.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma

  NCT06068400· Guangzhou Bio-gene Technology Co., Ltd· Frissítve: 2026. márc. 17.

  “Due to corporate strategic adjustment.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT07455851· Regeneron Pharmaceuticals· Forrás

• A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT04634552· Janssen Research & Development, LLC· Forrás

• AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

  NCT06106945· AstraZeneca· Forrás

• A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  NCT06615479· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Forrás

• Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06297226· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Forrás

• A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT06121843· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Forrás

• A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

  NCT05431608· Memorial Sloan Kettering Cancer Center· Forrás

• MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

  NCT04555551· Memorial Sloan Kettering Cancer Center· Forrás

• Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment

  NCT07195617· Guangzhou Bio-gene Technology Co., Ltd· Forrás

• A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

  NCT06630806· Sanofi· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 23
• Organoids 3
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 8
• Gene Expression Profiling 44
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 4
• Exome Sequencing 3
• Proteomics 15
• Metabolomics 10
• Mass Spectrometry 7
• Flow Cytometry 48
• Immunohistochemistry 11
• Liquid Biopsy 2
• Circulating Tumor DNA 2
• Xenograft Model Antitumor Assays 78
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 26
• Machine Learning 17
• Deep Learning 6
• Cohort Studies 32
• Genome-Wide Association Study 7

• Distinct 5' and 3' coverage biases shape transcriptome interpretation in Nanopore direct RNA versus PCR-cDNA sequencing.

  BMC Genomics, 2026. júl.

• The development of novel chimeric antigen receptor gamma-delta T cells against multiple myeloma and single-cell RNA sequencing analysis.

  Br J Haematol, 2026. júl.

• Single-cell RNA sequencing analysis revealed a potential association between ELK3 expression and the progression of multiple myeloma.

  Front Immunol, 2026. ápr.

• De Novo Detection of Clonal Structure and Evolution in Single-Cell and Spatial Transcriptomes.

  Int J Mol Sci, 2025. nov.

• Functional role of granulocytic myeloid-derived suppressor cells in CAR-T therapy: insights from single-cell RNA sequencing in multiple myeloma.

  Immunopharmacol Immunotoxicol, 2025. nov.

• Unravelling cell heterogeneity and gene regulation mechanisms in multiple myeloma through single-cell RNA-seq.

  Methods, 2025. nov.

• Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells.

  Leukemia, 2019. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.